The year in cardiology 2013: Valvular heart disease (focus on catheter-based interventions)

European Heart Journal

Volumn 35, Issue 8, 2014, Pages 490-494

  Grube, Eberhard ^a   Sinning, Jan Malte ^a   Vahanian, Alec ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b BICHAT HOSPITAL   (France)

Author keywords

Annular rupture; Anticoagulation; Aortic regurgitation; Aortic stenosis; Boston Lotus Valve; Co morbidities; CoreValve; Direct Flow Medical Valve; Durability; Edwards SAPIEN; Frailty; GARY; Intermediate risk; MitraClip; Mitral regurgitation; Mitral stenosis; New oral anticoagulants; NOAC; Outcome; Paravalvular aortic regurgitation; Paravalvular leakage; PMC; Risk; Stroke; TAVI; TAVR; TMVR; Valve in valve; Valvular heart disease; VIV

Indexed keywords

ANNULAR RUPTURE; ANTICOAGULATION; AORTIC REGURGITATION; AORTIC STENOSIS; BOSTON LOTUS VALVE; CO-MORBIDITIES; COREVALVE; DIRECT FLOW MEDICAL VALVE; DURABILITY; EDWARDS-SAPIEN; FRAILTY; GARY; INTERMEDIATE RISK; MITRACLIP; MITRAL REGURGITATION; MITRAL STENOSIS; NEW ORAL ANTICOAGULANTS; NOAC; OUTCOME; PARAVALVULAR AORTIC REGURGITATION; PARAVALVULAR LEAKAGE; PMC; RISK; STROKE; TAVI; TAVR; TMVR; VALVE-IN-VALVE; VALVULAR HEART DISEASE; VIV;

CARDIAC CATHETERIZATION; CARDIOLOGY; FORECASTING; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS;

EID: 84894524512     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht558     Document Type: Review

References (34)

1. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Oppell Von UO, Windecker S, Zamorano JL, Zembala M. Joint task force on the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012;33:2451-2496.
2. BerryC, Lloyd SM,WangY, MacDonald A, Ford I. The changing course of aortic valve disease in Scotland: temporal trends in hospitalizations and mortality and prognostic importance of aortic stenosis. Eur Heart J 2013;34:1538-1547.
3. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, Hung J. Differential left ventricular remodelling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J 2013;34:1906-1914.
4. O'Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, Buellesfeld L, Khattab AA, Nietlispach F, Moschovitis A, Zanchin T, Meier B, Windecker S,Wenaweser P. Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. Eur Heart J 2013;34:3437-3450.
5. Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuczu EM, Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, Williams M, Miller DC, Douglas PS, Leon MB. Predictors of mortality and outcomes of therapy in low flow severe aortic stenosis: a PARTNER trial analysis. Circulation 2013;127: 2316-2326.
6. Hamm CW, Mö llmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Bohm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S,Welz A, Mohr FW, for the GARY-Executive Board. The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J 2013; doi:10.1093/eurheartj/ eht381.
7. Mack MJ, Brennan M, Brindis R, Carroll J, Edwards F, Grover F, Shahian D, Tuzcu EM, Peterson ED, Rumsfeld JS, Hewitt K, Shewan C, Michaels J, Christensen B, Christian A, O'Brien S, Holmes D, for the STS/ACCTVTRegistry.Outcomes following transcatheter aortic valve replacement in the United States. JAMA 2013;310: 2069-2077.
8. Toggweiler S, Humphries KH, Lee M, Binder RK, Moss RR, Freeman M, Ye J, Cheung A,Wood DA,Webb JG. 5-year outcome aftertranscatheter aortic valve implantation. J Am Coll Cardiol 2013;61:413-419.
9. Van Mieghem NM, Schipper MEI, Ladich E, Faqiri E, van der Boon R, Randjgari A, Schultz C, Moelker A, van Geuns RJ, Otsuka F, Serruys PW, Virmani R, de Jaegere PP. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 2013;127:2194-2201.
10. Sinning JM, Vasa-Nicotera M, Chin D, Hammerstingl C, Ghanem A, Bence J, Kovac J, Grube E, Nickenig G,Werner N. Evaluation and management of paravalvular aortic regurgitation after transcatheter aortic valve replacement. J Am Coll Cardiol 2013;62: 11-20.
11. Barbanti M, Yang TH, Rodes-Cabau J, Tamburino C,Wood DA, Jilaihawi H, Blanke P, Makkar RR, Latib A, Colombo A, Tarantini G, Raju R, Binder RK, Nguyen G, Freeman M, Ribeiro HB, Kapadia S, Min J, Feuchtner G, Gurtvich R, Alqoofi F, Pelletier M, Ussia GP, Napodano M, de Brito FS, Kodali S, Norgaard BL, Hansson NC, Pache G, Canovas SJ, Zhang H, Leon MB,Webb JG, Leipsic J. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation 2013;128: 244-253.
12. Popma JJ, on behalf of the CoreValve US Clinical Investigators. CoreValve US Pivotal Trial Extreme Risk Iliofemoral Study Results. Presented 28 Nov 2013 at TCT 2013, San Francisco, USA.
13. Nazif TM, Williams MR, HahnRT, Kapadia S, BabaliarosV, Rodes-Cabau J, SzetoWY, Jilaihawi H, Fearon WF, Dvir D, Dewey TM, Makkar RR, Xu K, Dizon JM, Smith CR, Leon MB, Kodali SK. Clinical implications of new-onset left bundle branch block after transcatheter aortic valve replacement: analysis of the PARTNER experience. Eur Heart J 2013; doi:10.1093/eurheartj/eht376.
14. Testa L, Latib A, De Marco F, De Carlo M, Agnifili M, Latini RA, Petronio AS, Ettori F, Poli A, De Servi S, Ramondo A, Napodano M, Klugmann S, Ussia GP, Tamburino C, Brambilla N, Colombo A, Bedogni F. Clinical impact of persistent left bundle branch block after transcatheter aortic valve implantation with CoreValve Revalving System. Circulation 2013;127:1300-1307.
15. Schofer J, Colombo A, Klugmann S, Fajadet J, DeMarco F, Tchétché D, Maisano F, Bruschi G, Latib A, Bijuklic K, Weissman N, Low R, Thomas M, Young C, Redwood S, Mullen M, Yap J, Grube E, Nickenig G, Sinning JM, Hauptmann KE, Friedrich I, Lauterbach M, Schmoeckel M, Davidson C, Lefèvre T. Prospective Multicenter Evaluation of the Direct Flow Medicalw Transcatheter Aortic Valve. J Am Coll Cardiol 2013; 10.1016/j.jacc.2013.10.013.
16. Meredith IT, on behalf of the REPRISE II Investigators. REPRISE II: a prospective registry study of transcatheter aortic valve replacement with a repositionable transcatheter heart valve in patients with severe aortic stenosis. Presented 30 Nov 2013 at TCT 2013, San Francisco, USA.
17. Schoenenberger AW, Stortecky S, Neumann S, Moser A, Jüni P, Carrel T, Huber C, GandonM, Bischoff S, Schoenenberger CM, Stuck AE, Windecker S,Wenaweser P. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J 2013;34:684-692.
18. Wenaweser P, Stortecky S, Schwander S, Heg D, Huber C, Pilgrim T, Gloekler S, O'Sullivan CJ, Meier B, Jüni P, Carrel T, Windecker S. Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J 2013;34:1894-1905.
19. Goel SS, Ige M, Tuzcu EM, Ellis SG, Stewart WJ, Svensson LG, LytleBW, Kapadia SR. Severe aortic stenosis and coronary artery disease-implications for management in the transcatheter aortic valve replacement era: a comprehensive review. J Am Coll Cardiol 2013;62:1-10.
20. Barbanti M, Webb JG, Hahn RT, Feldman T, Boone RH, Smith CR, Kodali S, Zajarias A, Thompson CR, Green P, Babaliaros V, Makkar RR, Szeto WY, Douglas PS, McAndrew T, Hueter I, Miller DC, Leon MB, on behalf of the PARTNERTrial Investigators. Impact of preoperative moderate/severe mitral regurgitationon 2-yearoutcomeafter transcatheterand surgical aortic valve replacement: insight from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial Cohort A. Circulation 2013; doi:10.1161/CIRCULATIONAHA.113.003885.
21. Bedogni F, Latib A, De Marco F, Agnifili M, Oreglia J, Pizzocri S, Latini RA, Lanotte S, Petronio AS, De Carlo M, Ettori F, Fiorina C, Poli A, Cirri S, De Servi S, Ramondo A, Tarantini G, Marzocchi A, Fiorilli R, Klugmann S, Ussia GP, Tamburino C, Maisano F, Brambilla N, Colombo A, Testa L. Interplay between mitral regurgitation and transcatheter aortic valve replacement with the corevalve revalving system: a multicenter registry. Circulation 2013;128:2145-2153.
22. Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Möllmann H, Dumonteil N, Modine T, Bosmans J, Petronio AS, Moat N, Linke A, Moris C, Champagnac D, Parma R, Ochala A, Medvedofsky D, Patterson T, Woitek F, Jahangiri M, Laborde JC, Brecker SJ. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol 2013;61:1577-1584.
23. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, Smith PK, Hung JW, Blackstone EH, Puskas JD, Argenziano M, Gammie JS, Mack M, Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL, Miller MA, Woo YJ, D'Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ, O'Gara PT, Michler RE, Kron IL. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2013; doi: 10.1056/NEJMoa1312808.
24. Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, Hermiller J, Gray W, Wang A, Pedersen WR, Bajwa T, Lasala J, Low R, Grayburn P, Feldman T. EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J AmCollCardiol 2013;62:317-328.
25. Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, UssiaGP, Sievert H, Richardt G, Widder JD, Moccetti T, SchillingerW. Percutaneous mitral valve interventions in the real world: early and 1-year results from theACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052-1061.
26. Bouleti C, Iung B, Himbert D, Brochet E, Messika-Zeitoun D, Détaint D, Garbarz E, Cormier B, Vahanian A. Reinterventions after percutaneous mitral commissurotomy during long-termfollow-up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart J 2013;34:1923-1930.
27. Sinning JM, Mellert F, SchillerW,Welz A, Nickenig G, Hammerstingl C. Transcatheter mitral valve replacement using a balloon-expandable prosthesis in a patient with calcified native mitral valve stenosis. Eur Heart J 2013;34:2609-.
28. Dvir D,Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures F, Hengstenberg C, Moat NE, Bekeredjian R, Napodano M, Testa L, Lefevre T, Guetta V, Nissen H, Hernandez JM, Roy D, Teles RC, Segev A, Dumonteil N, Fiorina C, Gotzmann M, Tchetche D, Abdel-Wahab M, De Marco F, Baumbach A, Laborde JC, Kornowski R. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation 2012;126:2335-2344.
29. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, MaasH, Voigt J-U, Simoons ML, Van deWerf F. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-1214.
30. Gilard M. Key vignettes from the major TAVR country registries: France. Presented 28 Nov 2013 at TCT 2013, San Francisco, USA.
31. Moat N. Key vignettes from the major TAVR country registries: United Kingdom. Presented 28 Nov 2013 at TCT 2013, San Francisco, USA.
32. Tamburino C. Key vignettes from the majorTAVRcountry registries: Italy. Presented 28 Nov 2013 at TCT 2013, San Francisco, USA.
33. Wendler O. Important updates from the Edwards SAPIEN (and XT)SOURCEregistries. Presented 28 Nov 2013 at TCT 2013, San Francisco, USA.
34. Linke A. Important updates from the Medtronic CoreValve ADVANCE Registry. Presented 28 Nov 2013 at TCT 2013, San Francisco, USA.